December 22, 2025
1 min read

Samsung Biologics pays GSK $280M to secure first US manufacturing site

Samsung Bio’s U.S. subsidiary will pay $280 million to acquire GSK’s Human Genome Sciences and its two pharmaceutical manufacturing plants at a campus in Rockville, Maryland. The site, which will mark Samsung Bio’s first for production in the U.S., features a total 60,000 liters of drug substance capacity.

Leave a Reply

Your email address will not be published.

Previous Story

Nutrition Insight reviews 2025: AI tech, personalized solutions, and nutrition security in the GLP-1 era

Next Story

Incog to spend $200M on capacity boost at Indiana sterile injectables plant

Previous Story

Nutrition Insight reviews 2025: AI tech, personalized solutions, and nutrition security in the GLP-1 era

Next Story

Incog to spend $200M on capacity boost at Indiana sterile injectables plant

Latest from Blog

NEWS CENTER Maine

Through in-depth storytelling, through direct contact on digital on social platforms, through long-standing community service programs like Coats & Toys for Kids, Project Heat and Buddy to Buddy, NEWS CENTER Maine is
Go toTop